We have a 20-year track record of successful studies, multiple drug approvals, R&D collaborations, and commercial partnerships in oral healthcare. We are all Healthy Agers and Prevora patients.
Ross Perry, President, is responsible for drug approvals, key studies, and strategic direction in marketing.
Brenda Turgeon, VP Administration, is responsible for the Prevora supply chain, for regulatory audits, for working with our QC and QA advisor, and for the administration of drug licenses, inspections and intellectual property.
Bruce Burchart, VP, is building out the Canadian network of Partners in Prevention which serves Healthy Agers with affordable, preventive oral healthcare.
Gerry Salvati, VP Finance Responsibilities include financial reporting, tax, budgeting, forecasts and corporate finance.
Our clinical advisors
For years, CHX has worked closely with two leading clinicians on adapting Prevora to the treatment of Special Needs and Complex Needs patients, to the management of periodontal disease and to expanding the use of Prevora beyond traditional dental settings..
Dr. Howard C Tenenbaum is Professor of Periodontology, Faculty of Dentistry, as well as a Professor in the Department of Laboratory Medicine and Pathobiology at the University of Toronto. He is the former Dentist-in-Chief in the Department of Dentistry at Mount Sinai Hospital, Toronto. Dr. Tenenbaum pioneered the use of Prevora for adult patients with Special Needs including the frail elderly. Dr. Tenenbaum is a co-investigator on 2 studies underway with Prevora.
Ms. Julie DiNardo, RDH and owner of Gleam Smile Centre, Hamilton. Julie has hundreds of patients on Prevora and pioneered the rapid application technique for using Prevora in community settings. Ms. DiNardo is a co-investigator on one study underway with Prevora in a homecare setting.
For more information on Prevora and its unique contribution to preventive oral healthcare, send an email to info@prevora.com.
info@prevora.com